Genomic Biomarkers Market Report 2026

The genomic biomarkers market size has grown rapidly in recent years. It will grow from $8.72 billion in 2025 to $10.24 billion in 2026 at a compound annual growth rate (CAGR) of 17.5%. The growth in the historic period can be attributed to advancements in genomic sequencing technologies, expansion of oncology-focused biomarker research, increasing adoption of personalized treatment approaches, improvements in clinical validation frameworks, rising availability of genomic databases.

The genomic biomarkers market size is expected to see rapid growth in the next few years. It will grow to $19.33 billion in 2030 at a compound annual growth rate (CAGR) of 17.2%. The growth in the forecast period can be attributed to increasing investments in precision medicine programs, rising demand for early disease detection tools, expansion of biomarker-driven drug development, growing integration of ai in biomarker analysis, increasing regulatory support for personalized therapies. Major trends in the forecast period include increasing adoption of biomarker-guided precision medicine, rising integration of genomic data in clinical decision-making, growing use of companion diagnostics, expansion of multi-omics biomarker platforms, enhanced focus on clinical validation standards.

The growing demand for personalized medicine is expected to drive the growth of the genomic biomarkers market in the coming years. Personalized medicine, also called precision medicine, is a healthcare approach that customizes medical decisions and treatments to the unique characteristics of each patient, primarily based on their genetic and genomic information. This rising demand is fueled by factors such as increased focus on patient-centered care, advances in genetic sequencing and analysis, and the use of electronic health records (EHRs) to store and analyze patient data. Genomic biomarkers are integral to personalized medicine, allowing healthcare providers to tailor treatments according to an individual’s genetic profile. This approach optimizes treatment effectiveness and minimizes side effects by accounting for genetic differences among patients. For example, in February 2024, the Personalized Medicine Coalition, a US-based professional membership organization, reported that the FDA approved 16 new personalized therapies for rare disease patients in 2023, compared with six approvals in 2022. Consequently, the rising adoption of personalized medicine is driving the genomic biomarkers market.

Leading companies in the genomic biomarkers market are focused on developing innovative products, such as lung reagents, to improve the detection of specific genetic mutations in lung cancer, enhance diagnostic accuracy, and support personalized treatment strategies through advanced genomic technologies. Lung reagents are specialized chemical or biological substances used in diagnostic tests, research, or medical procedures related to the lungs, helping guide precision medicine by identifying the genetic profile of the cancer. For instance, in December 2023, Biofidelity, a UK-based company specializing in advanced genomic assays and precision diagnostics, launched ASPYRE-Lung reagents. These reagents are designed to detect key genetic mutations and alterations in lung cancer, which are critical for guiding targeted therapies and personalized treatment strategies.

In October 2025, Guardant Health, Inc., a US-based precision oncology company, formed a strategic partnership with Zephyr AI, Inc., a US-based precision medicine company specializing in artificial intelligence. This collaboration aims to accelerate the development of novel cancer biomarkers by combining Guardant Health’s multimodal molecular and real-world oncology data with Zephyr AI’s advanced AI and machine learning analytics platform. Zephyr AI applies AI and ML technologies to support biomarker discovery, drug development, and personalized treatment strategies.

Major companies operating in the genomic biomarkers market are Thermo Fisher Scientific Inc., Roche Diagnostics International Ltd., Illumina Inc., PerkinElmer Inc., Almac Group, Azenta Inc., Novogene Corporation, Oxford Nanopore Technologies Ltd., Celerion, Quanterix Corporation, Bio-Rad Laboratories Inc., NantHealth Inc., Centogene N.V., Sophia Genetics SA, Envisagenics, Deep Genomics, Creative Diagnostics, Macrogen Inc., Guardant Health Inc., Sema4.

North America was the largest region in the genomic biomarkers market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the genomic biomarkers market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the genomic biomarkers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the genomic biomarkers market by increasing costs of imported sequencing systems, reagents, diagnostic instruments, and bioinformatics infrastructure used in biomarker discovery and validation. Hospitals, diagnostic centers, and research facilities in north america and europe are most affected due to dependence on imported genomic technologies, while asia-pacific faces cost pressures on biomarker testing services. These tariffs are increasing testing costs and slowing adoption in routine diagnostics. However, they are also encouraging domestic diagnostics manufacturing, regional innovation, and localized genomic testing capabilities.

The genomic biomarkers market research report is one of a series of new reports that provides genomic biomarkers market statistics, including genomic biomarkers industry global market size, regional shares, competitors with a genomic biomarkers market share, detailed genomic biomarkers market segments, market trends and opportunities, and any further data you may need to thrive in the genomic biomarkers industry. This genomic biomarkers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Genomic biomarkers are specific DNA or RNA sequences or variations that provide insights into biological processes, conditions, or responses to particular treatments. These biomarkers are widely used in precision medicine to predict disease risk, diagnose conditions, monitor disease progression, and guide treatment decisions. They play a vital role in personalized medicine by enabling healthcare providers to tailor therapies based on an individual’s genetic profile, thereby enhancing treatment effectiveness and reducing the risk of adverse effects.

The primary types of genomic biomarkers include predictive biomarkers and prognostic biomarkers. Predictive biomarkers are biological molecules present in blood, other body fluids, or tissues that indicate whether a patient is likely to respond positively to a specific medical treatment or intervention. These biomarkers are applied across various disease areas, including oncology, cardiovascular diseases, neurological disorders, renal diseases, and others, and undergo validation processes such as analytical validation, clinical validation, and assessment of clinical utility. They are utilized by multiple end-users, including hospitals, diagnostic centers, and related healthcare facilities.

The genomic biomarkers market consists of sales of genomic biomarker panels, real-time PCR detection systems, and droplet digital PCR (ddPCR) systems. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.